Mar 2, 2009 | Laboratory News, Laboratory Pathology
Acquisition will particularly strengthen Beckman’s presence in clinical chemistry market
Monday, March 2, 2009
Last Friday, Beckman Coulter Inc. (NYSE:BEC) announced that it will pay $800 million acquire the diagnostics business of Olympus Corporation. This is a major transaction that further consolidates the in vitro diagnostics (IVD) industry, particularly given the respective market shares in clinical chemistry currently held by both Beckman and Olympus. (more…)
Oct 24, 2008 | Laboratory Management and Operations, Laboratory Pathology
Use of antibodies that detect biomarkers in as little as 15 minutes now allows researchers at the University of Leeds in the United Kingdom to identify such diseases as prostate and ovarian cancer, stroke, multiple sclerosis (MS), heart disease, and fungal infections. Using biosensors to identify the molecular markers for disease, the technology is much faster than current testing methods.
One goal of this research is to provide a way for hospitals to use this technology for rapid diagnosis. Another goal is to allow surgeons to use the technology to improve the speed and accuracy of referral to specialty physicians. Along with the ability to identify cancer, MS, heart disease, and infections, researchers say these biosensors may also be able to detect a wide range of analytes, including biomarkers in tuberculosis and HIV.
“We believe this to be the next generation diagnostic testing. We can now detect almost any analyte faster, cheaper, and more easily than the current accepted testing methodology,” said Paul Millner, M.D, a member of the faculty of Biological Sciences at the University of Leeds.
Researchers say that this technology could be developed into a device the size of a mobile phone, where different sensor chips could be inserted, depending on the disease being sought. “We’ve designed simple instrumentation to make the biosensors easy to use and understand,” Millner explained. “They’ll work in a format similar to the glucose biosensor testing kits that diabetics use.”
Currently blood and urine are tested for disease markers using test technologies such as ELISA (enzyme-linked immunosorbant assay). Developed in the 1970s, ELISA takes an average of two hours to complete, can be expensive, and can be performed only by highly trained staff.
The new biomarker technology was developed through a European collaboration of researchers and commercial partners in a 2.7 million Euro ($3.6 million) project called ELISHA (Electronic Immuno-Interfaces and Surface Nanobiotechnology: A Heterodoxical Approach).
Related Information
Oct 22, 2008 | Laboratory News, Laboratory Pathology
Siemens AG has introduced a PDA-sized portable ultrasound machine dubbed the P10 that allows emergency room doctors to assess patients quickly and easily. Devices like the P10 are possible largely because analog chip makers are racing to develop electronics that allow portability. Like cell phones before them, these portable ultrasound machines will become increasingly smaller, faster, and cheaper over time. They will also consume far less power than their full-sized counterparts.
Technology advances like these will also trigger new, smaller analyzers for in vitro diagnostics. The explosive growth in this market is demonstrated by a simple fact: semiconductor sales associated with medical equipment totaled $3.02 billion in 2007, up 65% from 5 years ago! Sales of portable systems-those weighing less than 11 lbs-climbed 42% to $565 million last year and are forecasted to reach $1.2 billion in 5 years, according to Klein Biomedical Consultants, Inc., General Electric Co’s GE Healthcare, SonoSite Inc., and Zonare Medical Systems, Inc. together accounted for 85% of the market in 2007.
These portable devices are expected to make ultrasound, which has traditionally been limited to radiologists, cardiologists, obstetricians, and gynecologists, available to new classes of specialists, including anesthesiologists and emergency care physicians. The expanded use of ultrasound could help cut healthcare costs through earlier and more accurate diagnoses.
Technology incorporated in the P10 and other portable ultrasound devices does need improvement. For example, the P10 currently does no show color, so doctors won’t see some problems. Its battery life is limited to four hours of normal use. Refinements to improve image quality and reduce power usage in the pipeline and will soon reach clinical use.
The refinement of computing chips for use in portable ultrasound devices is of note to laboratory staff because this technology has easy applications in creating more and better portable laboratory testing devices. That will expand the types of near patient and point-of-care (POC) testing systems available for diagnostic purposes. It will also enable a new generation of patient self test systems to find ready acceptance by patients. In fact, the development of blood glucose monitoring systems for diabetic patients provides one good example of how manufacturers are regularly adding new features and capabilities to these consumer self-test products.
Related Articles:
Chip Advances Lift Ultrasound Market, Help Save Lives
